Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Aerobic Exercise, Breast Cancer, Arteria...
Phase NA
Enrollment 18
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study was to evaluate vascular toxicity induced by anthracyclines and other anticancer drugs and to measure arterial stiffness in women with breast cancer and, in addition, to evaluate the acute and chronic arterial stiffness responses of upper extremity aerobic exercise training.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Upper Extremity Aerobic Exercise Training Program — 12 weeks of supervised upper limb aerobic exercise training, 3 sessions per week, 25 minutes per session.

Primary Outcomes

  • Arterial Stiffness (one years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-08
Completion: 2026-12-01
Eligibility
Age: 40 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 18 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hacettepe University
Principal Investigators:
  • Melda Saglam, PhD (STUDY_CHAIR) - Hacettepe University
  • Ebru Calik Kutukcu, PhD (STUDY_DIRECTOR) - Hacettepe University
Contact Information
Study Contact:
Ebru Calik Kutukcu, PhD
+903123051576
ebru.calik@hacettepe.edu.tr
Naciye Vardar-Yagli, PhD
+03123051576
naciyevardar@yahoo.com
Ebru Calik Kutukcu, PhD
+903123051576
ebru.calik@hacettepe.edu.tr
Hacettepe University
Interventions
  • Other: Upper Extremity Aerobic Exercise Training Program — 12 weeks of supervised upper limb aerobic exercise training, 3 sessions per week, 25 minutes per session.
Study Locations (1 sites)
Hacettepe University, Ankara, State 06100 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * To be between the ages of 40-69, * Baseline left ventricular ejection fraction (LVEF) \>50%, * Absence of coronary artery disease and haemodynamically significant valvular heart disease, * Absence of carotid atherosclerotic plaques, * Volunteering to participate in the research, * At least 15 months after breast cancer surgery, * No problems in reading and/or understanding the scales and being able to co-operate with the tests. * Physically inactive (60 minutes of structured exercise per week \<). Exclusion Criteria: * Presence of active infection, * Presence of bilateral breast cancer, * History of surgical, neurological or orthopaedic problems that may affect upper extremity functionality other than breast cancer surgery, * Having a neurological disease or other clinical diagnosis that may affect cognitive status, * Left ventricular dysfunction and severe liver and kidney dysfunction before starting chemotherapy * Musculoskeletal and neurological disease that may affect exercise performance, symptomatic heart disease, previous lung surgery and malignant disease. * Presence of unstable hypertension or diabetes mellitus.
Conditions Major Depressive Disorder (MDD) With Ins...
Phase PHASE3
Enrollment 184
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Major Depressive Disorder (MDD) affects 5% of the global population and is the second leading cause of disability worldwide. Despite the widespread use of antidepressants, 50-60% of patients do not respond adequately after 8 weeks of treatment. Insomnia, present in approximately 85% of individuals with MDD, is a frequent and persistent symptom that contributes to poor treatment outcomes. Targeting insomnia has been shown to enhance both symptom remission and functional recovery. In this context, combined therapeutic strategies are often used to optimize the antidepressant response. Among them, chronotherapeutic approaches, such as light therapy and prolonged-release melatonin, have demonstrated rapid antidepressant effects and are beneficial in regulating sleep and circadian rhythms. Light therapy shows an efficacy comparable to antidepressants and, when used in combination with them, can double treatment effectiveness. Melatonin is also recommended in the management of depression-related insomnia. This multicenter, randomized, double-blind, placebo-controlled trial with a 2x2 factorial design aims to evaluate the efficacy of two chronotherapeutic interventions, 8 weeks of active light therapy and 2 mg of prolonged-release melatonin-administered alone or in combination, on depressive symptom reduction at 8 weeks in adult patients with MDD and comorbid insomnia. The primary outcome is the change in Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline to week 8. All participants will receive antidepressant treatment and sleep hygiene education. This study proposes a novel therapeutic strategy combining pharmacological and non-pharmacological interventions to address both depression and insomnia, with the goal of improving outcomes, especially for the 40% of patients who do not adequately respond to antidepressants alone.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Factorial Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Procedure: AD + SHR + active LT and extended-release melatonin 2mg — Patients will receive an SSRI antidepressant (e.g., Fluoxetine, Sertraline, Paroxetine, Escitalopram) or SNRI (e.g., Venlafaxine, Duloxetine) antidepressant (as clinically appropriate), combined with sleep hygiene education, daily morning LT (10,000 lux for 30 minutes between 7-8 a.m. using the Dayvia Slim Style 3 lamp), and 2 mg of extended-release melatonin taken one hour before bedtime, all for a duration of 8 weeks.
  • Procedure: AD + SHR + active LT and placebo melatonin — Patients will receive an SSRI or SNRI, sleep hygiene instructions, daily morning bright LT (10,000 lux, 30 cm, 30 min, 7-8 a.m., using Dayvia Slim Style 3 lamps), and placebo melatonin taken one hour before bedtime, all for a duration of 8 weeks.
  • Procedure: AD + SHR + placebo LT and extended-release melatonin 2mg — Patients will receive an SSRI or SNRI, sleep hygiene instructions, daily placebo light exposure (\<10 lux, 30 cm, 30 min, 7-8 a.m., using Dayvia Slim Style 3 lamps in non-therapeutic mode), and 2 mg of extended-release melatonin taken one hour before bedtime, all for a duration of 8 weeks.
  • Procedure: AD + SHR + placebo LT and placebo melatonin — Patients will receive an SSRI or SNRI, sleep hygiene instructions, daily placebo light exposure (\<10 lux, 30 cm, 30 min, 7-8 a.m., using Dayvia Slim Style 3 lamps), and oral placebo melatonin taken one hour before bedtime, all for a duration of 8 weeks.

Primary Outcomes

  • Assessment of the efficacy of two chronotherapeutics (LT and extended-release melatonin 2mg), alone or combined, associated to AD on depressive symptoms reduction after 8 weeks of treatment (At baseline (Week 0) and at Week 8)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-01-28
Completion: 2029-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 184 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Assistance Publique - Hôpitaux de Paris
Principal Investigators:
  • Pierre-Alexis GEOFFROY, Pr (PRINCIPAL_INVESTIGATOR) - Assistance Publique - Hôpitaux de Paris
Contact Information
Study Contact:
Pierre-Alexis GEOFFROY, Pr, med
+33 1 40 25 62 72
pierrealexis.geoffroy@aphp.fr
Julia MARUANI, Dr, med
+33 1 40 25 62 72
julia.maruani@aphp.fr
Pierre-Alexis GEOFFROY, Pr, med
+33 1 40 25 62 72
pierrealexis.geoffroy@aphp.fr
Hôpital Bichat-Claude Bernard
Interventions
  • Procedure: AD + SHR + active LT and extended-release melatonin 2mg — Patients will receive an SSRI antidepressant (e.g., Fluoxetine, Sertraline, Paroxetine, Escitalopram) or SNRI (e.g., Venlafaxine, Duloxetine) antidepressant (as clinically appropriate), combined with sleep hygiene education, daily morning LT (10,000 lux for 30 minutes between 7-8 a.m. using the Dayvia Slim Style 3 lamp), and 2 mg of extended-release melatonin taken one hour before bedtime, all for a duration of 8 weeks.
  • Procedure: AD + SHR + active LT and placebo melatonin — Patients will receive an SSRI or SNRI, sleep hygiene instructions, daily morning bright LT (10,000 lux, 30 cm, 30 min, 7-8 a.m., using Dayvia Slim Style 3 lamps), and placebo melatonin taken one hour before bedtime, all for a duration of 8 weeks.
  • Procedure: AD + SHR + placebo LT and extended-release melatonin 2mg — Patients will receive an SSRI or SNRI, sleep hygiene instructions, daily placebo light exposure (\<10 lux, 30 cm, 30 min, 7-8 a.m., using Dayvia Slim Style 3 lamps in non-therapeutic mode), and 2 mg of extended-release melatonin taken one hour before bedtime, all for a duration of 8 weeks.
  • Procedure: AD + SHR + placebo LT and placebo melatonin — Patients will receive an SSRI or SNRI, sleep hygiene instructions, daily placebo light exposure (\<10 lux, 30 cm, 30 min, 7-8 a.m., using Dayvia Slim Style 3 lamps), and oral placebo melatonin taken one hour before bedtime, all for a duration of 8 weeks.
Study Locations (1 sites)
Hôpital Bichat-Claude Bernard, Paris, 75018 France
Eligibility Criteria
Inclusion Criteria: 1. Adults aged between 18 and 65 years (to avoid the risk of cataract associated with light therapy) with a diagnosis of a major depressive episode (MDE) in the context of unipolar depression (according to DSM-5 criteria). 2. Diagnosis of comorbid insomnia with the MDE, defined by difficulty initiating sleep, and/or maintaining sleep, and/or early morning awakenings with daytime consequences, occurring at least three times per week (according to DSM-5 and ICSD-3, in line with European guideline recommendations). 3. Outpatients or inpatients treated for MDE in one of the psychiatric departments of the study centers, or in the sleep medicine department, for a minimum treatment duration of 8 weeks. 4. Patients not currently receiving antidepressant treatment for the current MDE (previous use of antidepressants is allowed, provided treatment was stopped at least one month prior to study participation). 5. A MADRS score ≥ 20 (clinician-rated), indicating at least a moderate-intensity depressive episode. 6. An ISI score ≥ 8 (clinician-rated), indicating at least mild and clinically significant insomnia. 7. No exposure to light therapy in the month prior to inclusion. 8. Ability to understand and sign the informed consent form. 9. Use of highly effective contraception for women of childbearing potential. Exclusion Criteria: 1. Individuals under legal guardianship or deprived of liberty 2. Ophthalmologic conditions (e.g., cataract, glaucoma, age-related macular degeneration) or diseases affecting the retina (e.g., retinitis pigmentosa, diabetes, herpes, etc.) 3. The following disorders (according to DSM-5): schizophrenia and other psychotic disorders; bipolar disorder, particularly (hypo)manic episodes (YMRS score ≥ 12); other unstable mental disorders 4. Other unstable general medical conditions 5. Pregnant or breastfeeding women 6. Hypersomnia with prolonged total sleep time secondary to the depressive episode, according to ICSD-3 criteria 7. Current depressive episode already being treated with an antidepressant 8. Presence of a high suicidal risk, as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS, score ≥ 4) 9. Ongoing melatonin treatment at the time of inclusion
Conditions Breast Cancer Screening
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is an observational study to evaluate the MAMMOMAT B.brilliant system. All diagnostic decisions are made by the treating radiologist based upon standard of care clinical imaging acquired on FDA approved devices

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Breast Imaging — Intervention using an FDA-approved mammogram machine.

Primary Outcomes

  • Comparison of two Siemen System B.brillant and the Revelation (From enrollment to the end of study at 18 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-12-15
Completion: 2027-01-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Pennsylvania
Collaborators: Siemens Corporation, Corporate Technology
Principal Investigators:
  • Brian S Englander, MD (PRINCIPAL_INVESTIGATOR) - Pennsylvania Hospital
Contact Information
Study Contact:
Namaijah Faison Clinical Research Coordinator
215-432-5000
Namaijah.Faison@pennmedicine.upenn.edu
Jessica Nunez Project Manager
215-829-3712
Jessica.Nunez@pennmedicine.upenn.edu
Jessica Nunez
215-829-3712
Jessica.Nunez@pennmedicine.upenn.edu
Pennsylvania Hospital, Center for Breast Imaging
Interventions
  • Diagnostic Test: Breast Imaging — Intervention using an FDA-approved mammogram machine.
Study Locations (1 sites)
Pennsylvania Hospital, Center for Breast Imaging, Philadelphia, Pennsylvania 19107 United States
Eligibility Criteria
Inclusion Criteria 1. Participants will be ≥ 18 years of age. 2. Participants will be females (sex assigned at birth). 3. Participants will be presenting for clinical diagnostic mammography with suspicious calcifications or calcifications associated with other lesion types 4. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures. Exclusion Criteria 1. Females who are breast-feeding will not be eligible for this study 2. Pregnant women will not be included. All females of childbearing potential must attest that they are not pregnant. 3. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician. 4. Any current medical condition, illness, or disorder, as assessed by medical record review and/or self-reported, that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study.
Conditions Major Depression Disorder, Cognitive Def...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Multimodal study (Behavior, TMS, EEG) combining a sham-controlled intermittent theta burst stimulation (iTBS) intervention with an additional-singleton task and EEG to evaluate whether left dorsolateral prefrontal cortex (DLPFC) stimulation enhances cognitive control and modulates maladaptive attention processes in MDD and whether the effects are influenced by neuronavigated versus manual (Beam F3 method) localization of the stimulation site.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: intermittent theta burst stimulation (iTBS) intervention — iTBS protocol: Intervention with an 80-120% resting threshold was used. In the active group, the left dlPFC was selected as the stimulation site and a stimulation protocol with iTBS parameters was given. This was a neuro-modulation protocol of excitatory sequences, with theta burst stimulation at 50 Hz, repeated at 5 Hz, stimulation for 2 s with an interval of 8 s, for a total of 1,800 pulses, with a treatment time of about 20 min/session, two sessions per day, with a15-30 min rest between sessions, and five consecutive days of treatment per week, with a rest of 2 days, and two weeks of treatment.

Primary Outcomes

  • Depression severity following two weeks of iTBS treatment. (60-90 minutes before the first iTBS treatment and 60-90 minutes after last iTBS treatment.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-01
Completion: 2028-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Electronic Science and Technology of China
Contact Information
Study Contact:
Nan Qiu, PhD
86 18380456153
shirleyqiunan@gmail.com
The Clinical Hospital of Chengdu Brain Science Institute, Chengdu Fourth People's Hospital, Jiujiang Branch (Chengdu Mental Health Center)
Lan Hu, PhD
86 02887038120
The Clinical Hospital of Chengdu Brain Science Institute, Chengdu Fourth People's Hospital, Jiujiang Branch (Chengdu Mental Health Center)
Interventions
  • Device: intermittent theta burst stimulation (iTBS) intervention — iTBS protocol: Intervention with an 80-120% resting threshold was used. In the active group, the left dlPFC was selected as the stimulation site and a stimulation protocol with iTBS parameters was given. This was a neuro-modulation protocol of excitatory sequences, with theta burst stimulation at 50 Hz, repeated at 5 Hz, stimulation for 2 s with an interval of 8 s, for a total of 1,800 pulses, with a treatment time of about 20 min/session, two sessions per day, with a15-30 min rest between sessions, and five consecutive days of treatment per week, with a rest of 2 days, and two weeks of treatment.
Study Locations (1 sites)
The Clinical Hospital of Chengdu Brain Science Institute, Chengdu Fourth People's Hospital, Jiujiang Branch (Chengdu Mental Health Center), Chengdu, Sichuan 610041 China
Eligibility Criteria
Inclusion Criteria: * 18-55 years * Right-handed * Normal or corrected normal visual acuity * MDD: meet the proposed DSM-5 MDD criteria, unmedicated or stable medicated within the last one month. Healthy subjects without any past or present psychiatric or neurological disorders. Exclusion Criteria: * Diagnosis of other severe mental disorders, such as schizophrenia, bipolar disorder, neurodevelopmental disorder, etc. * high suicidal risk * Unnormal intellectual functioning, auditory impairments, * Have received neuromodulation, such as Modified Electroconvulsive Therapy (MECT), or any psychotherapy within the past 6 months. * Only for the active-iTBS group: have a contraindication to MRI scanning (e.g., metal implants, claustrophobia or other conditions that make them inappropriate for MRI scanning).
Conditions Breast Cancer, Axillary Lymph Nodes Diss...
Phase Not Applicable
Enrollment 400
Locations 12 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Axillary ultrasound scan (AUS) is routinely employed in the UK for preoperative axillary staging and can diagnose approximately 50 - 80% of node positive patients when combined with percutaneous needle biopsy techniques (either core-biopsy or fine-needle aspiration cytology). It is recognised that nodal burden is generally higher in clinically node negative patients with abnormal nodes on AUS and confirmed on needle-biopsy to be histologically positive than patients diagnosed as node positive on sentinel node biopsy (SNB). However, up to 40% of biopsy-proven node positive patients are found to have fewer than 3 involved nodes on subsequent axillary lymph node dissection (ALND) and are potential candidates for less extensive axillary surgery with axillary radiotherapy (ART) rather than ALND. The total number of abnormal nodes on ultrasound is a key predictor of overall nodal tumour burden. The AMAROS and OTOASOR trials randomised patients with up to 2 positive sentinel nodes to either ALND or ART. These trials were conducted around the turn of the millennium and before routine use of AUS and therefore would have included a significant number of patients who were radiologically node positive (cN1). Likewise, the ACOSOG Z0011 trial that randomised a similar group of patients to either ALND or observation only, did not incorporate routine AUS and would have included some (radiological) cN1 patients. These trials revealed no adverse impact on disease-free or overall survival from omission of completion ALND. Targeted axillary dissection (TAD) was introduced a few years ago to reduce the false negative rate of SNB following neoadjuvant chemotherapy (NACT) and has been standardised as part of the ongoing ATNEC trial \[ClinicalTrials.govNCT04109079\]. This technique for axillary staging after NACT is increasingly being adopted in the UK and elsewhere. TAD is technically more straightforward and less challenging in patients undergoing primary surgery with no concerns about clip migration consequent to nodal shrinkage as part of treatment response to NACT. Furthermore, the risk of under-treating the axilla is offset by the protocol: if no disease is identified in the targeted nodes (false-negative case), then patients proceed to ALND, thereby ensuring adequate treatment. Unlike TAD following NACT, the presence of viable tumour within the sampled nodes is mandatory and finding fibrosis is irrelevant except as a response to nodal biopsy per se. Current ASCO guidelines support both SNB and TAD as staging options for patients with ultrasound-detected, biopsy-confirmed nodal disease. The Edinburgh randomised trials comparing four-node sampling with ALND demonstrated significantly lower arm morbidity with node sampling, supporting TAD as a less morbid appropriate alternative in this patient population. The UK-ANZ POSNOC trial randomised 1,900 patients with \<3 macrometastases to either no further axillary treatment or additional axillary treatment. The…

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Targeted Sentinel Node Biopsy (TSNB) — Targeted Sentinel Node Biopsy will be performed according to routine local practice. The procedure has been standardised for the post-NACT setting as part of the ongoing ATNEC trial. Sites are advised to follow the ATNEC protocol in the primary surgery setting, using either a dual- or single-tracer sentinel node biopsy technique, with localisation and removal of the marked biopsy proven positive node, and removal of at least 3 nodes. Axillary treatment following TSNB will be determined according to local MDT recommendations.

Primary Outcomes

  • Patients with ≤2 nodal macrometastases identified on histology. (12 months)
  • Patients with ≤2 nodal macrometastases identified on histology. (24 months)
  • Patients with ≤2 nodal macrometastases identified on histology. (36 months)
  • Patients with ≤2 nodal macrometastases identified on histology. (48 months)
  • Patients with ≤2 nodal macrometastases identified on histology. (60 months)
  • Identification rate of marked node (12 months)
  • Identification rate of marked node (24 months)
  • Identification rate of marked node (36 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-01-17
Completion: 2033-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospitals of Derby and Burton NHS Foundation Trust
Principal Investigators:
  • Amit Goyal (STUDY_CHAIR) - University Hospitals of Derby and Burton NHS Foundation Trust
Contact Information
Study Contact:
Amit Goyal
01332 786958
amit.goyal@nhs.net
Inder Kumar
Inder.Kumar@elht.nhs.uk
Burnley General Teaching Hospital
Inder Kumar
Burnley General Teaching Hospital
Interventions
  • Procedure: Targeted Sentinel Node Biopsy (TSNB) — Targeted Sentinel Node Biopsy will be performed according to routine local practice. The procedure has been standardised for the post-NACT setting as part of the ongoing ATNEC trial. Sites are advised to follow the ATNEC protocol in the primary surgery setting, using either a dual- or single-tracer sentinel node biopsy technique, with localisation and removal of the marked biopsy proven positive node, and removal of at least 3 nodes. Axillary treatment following TSNB will be determined according to local MDT recommendations.
Study Locations (12 sites)
Burnley General Teaching Hospital, Burnley, United Kingdom
Addenbrooke's Hospital, Cambridge, United Kingdom
University Hospitals of Derby and Burton, Derby, United Kingdom
Gartnavel General Hospital, Glasgow, United Kingdom
Wycombe Hospital, High Wycombe, HP11 2TT United Kingdom
Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom
Royal Alexandra Hospital, Paisley, United Kingdom
The Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, United Kingdom
Mersey and West Lancashire Teaching Hospitals, St Helens, United Kingdom
University Hospital of North Tees and Hartlepool, Stockton-on-Tees, United Kingdom
Eligibility Criteria
Inclusion Criteria: * cT1-2N1M0 breast cancer\* * FNA or core biopsy confirmed axillary nodal metastases * ≤2 abnormal nodes on imaging * Undergo a dual tracer or single tracer sentinel node biopsy along with removal of the marked node (Targeted Sentinel Node Biopsy, TSNB) * 1 or 2 macrometastases identified in the removed nodes, with at least three nodes removed * If the sentinel node(s) cannot be localised on SNB: axillary node sampling should be performed, the patient will be eligible if 1 or 2 macrometastases are identified in the removed nodes, with at least three nodes removed. * If the node is not marked or the marked node is not removed, the patient will be eligible if 1 or 2 macrometastases are identified in the removed nodes, with at least three nodes removed‡. * patients with T3 tumours on post-operative histology will remain eligible. For multifocal/multicentric tumours, the T stage is based on the size of the largest invasive tumour focus rather than the combined size of all tumours. * If \<3 lymph nodes are identified on histology, patient will remain in the NodeSMART registry. The decision regarding any further axillary treatment will be made by the treating MDT and recorded in the registry. Exclusion Criteria: * Neoadjuvant chemotherapy * Previous ipsilateral axillary lymph node dissection * cT3-4 breast cancer * ≥3 abnormal nodes on imaging
Conditions Preeclampsia (PE), Fetal Growth Restrict...
Phase Not Applicable
Enrollment 2000
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The project is a national, prospective, multicenter pilot project. The project is focus on setting up the combined first trimester screening in the Czech Republic. The combined first trimester screening is aimed at predicting and detecting the most serious obstetric complications, such as the great obstetrical syndromes (preeclampsia, fetal growth restriction, preterm labor and intrauterine fetal demise "IUFD") and structural congenital defects (morphological and chromosomal). The primary objective of the project is to create a unified methodology for performing and evaluating the combined first trimester screening in connection with the National Health Information System (hereinafter referred to as "NHIS"), which will enable recording, providing analysis and linking recorded clinical parameters with data in the NHIS. The pilot project will also provide data for modeling appropriate mechanisms for reimbursement from public health insurance.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Proportion of women with identified increased risk of Preeclampsia, Fetal Growth Restriction or Fetal Chromosomal Aneuploidies (trisomies of chromosomes 21, 18 and 13) (From June 2025 to October 2026)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-06-15
Completion: 2027-04-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institute of Health Information and Statistics of the Czech Republic
Collaborators: University Hospital Olomouc, Institute for the Care of Mother and Child, Prague, Czech Republic, Krajská zdravotní, a.s. - Nemocnice Most, o.z.
Principal Investigators:
  • Marek Ľubušký, prof. (STUDY_DIRECTOR) - THE FETAL MEDICINE CENTRE, Department of Obstetrics and Gynecology, Palacky University Olomouc, Faculty of Medicine and Dentistry, University Hospital Olomouc
Contact Information
Study Contact:
Petra Brlica Heideová, Msc.
+420 770 171 533
Petra.BrlicaHeideova@uzis.cz
Lucie Mandelová, PhD
+420 770 190 828
lucie.mandelova@uzis.cz
Marian Kacerovský, Prof.
+420777657991
KacerovskyM@lfhk.cuni.cz
Regional Health Corpotarion - Most Hospital
Interventions
N/A
Study Locations (3 sites)
Regional Health Corpotarion - Most Hospital, Most, Czechia Czechia
University Hospital Olomouc, Olomouc, Czechia Czechia
Institute for the Care of Mother and Child, Prague, Czechia Czechia
Eligibility Criteria
Inclusion Criteria: * A woman over 18 years old in the first trimester of pregnancy (11th-13th gestational week) * Signed the Consent to Participate in the Project and GDPR. Exclusion Criteria: * Unsigned the Consent to Participate in the Project and the Consent to the Processing of Personal Data.
Conditions Hypertension
Phase NA
Enrollment 190
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to explore the barriers and facilitators to adopting a reduced dietary salt and increased potassium intake among adults with essential hypertension in Singapore, and to evaluate the feasibility and preliminary effectiveness of a newly developed educational tool-Decreased Salt High Potassium (DSHP) Diet Tool-in reducing dietary sodium intake and increasing potassium intake. This three-part study will involve adults aged 21 years and above, with a self-reported diagnosis of hypertension for at least six months and/or currently taking antihypertensive medication. Participants will be recruited from two SingHealth Polyclinics (Punggol Polyclinic and Pasir Ris Polyclinic). Healthcare providers (HCPs) working at these clinics who have experience in managing patients with hypertension and in educating patients on reducing dietary sodium intake will also be recruited. The main questions this study aims to answer are: * What are the perceived barriers and facilitators for patients with hypertension to reduce dietary sodium and increase potassium intake? * What are the perceived barriers and facilitators experienced by healthcare providers in educating patients about sodium reduction and potassium intake? * Is the DSHP Diet Tool feasible and effective in reducing dietary sodium intake and increasing potassium intake among patients with hypertension? Participants in the intervention group will be provided DSHP Diet Tool and Decreased Salt High Potassium patient information leaflet (DSHP PIL). Participants in the control group will receive standard care and a patient information leaflet (DSHP PIL). Researchers will compare participants in the intervention group to the control group to determine whether the DSHP tool is effective in reducing dietary sodium and increasing potassium intake in patients with hypertension.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Decreased Salt High Potassium Tool (DSHP Tool) — Participants in this arm will receive standard hypertension care and the Decreased Salt High Potassium (DSHP)Tool for 24 weeks. The DSHP Tool is an educational resource which includes a sodium intake calculator and tracker, potassium-rich food lists, risk matrix visuals, goal-setting modules tailored to the Singaporean diet. Participants will also receive the DSHP Patient Information Leaflet (PIL) .

Primary Outcomes

  • 24 hour Urinary Sodium level (At baseline and at the end of the intervention (24 weeks))
  • 24 hour urinary potassium level (at baseline and at the end of intervention (24 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-01
Completion: 2030-07-31
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: false
Enrollment: 190 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Jingfeng
Contact Information
Study Contact:
SUN JINGFENG, Masters in Medicine(Fam Med)
+6591390121
jingfengsun88@gmail.com
Jingfeng Sun
91390121
sun.jingfeng@singhealth.com.sg
Jingfeng Sun
Interventions
  • Behavioral: Decreased Salt High Potassium Tool (DSHP Tool) — Participants in this arm will receive standard hypertension care and the Decreased Salt High Potassium (DSHP)Tool for 24 weeks. The DSHP Tool is an educational resource which includes a sodium intake calculator and tracker, potassium-rich food lists, risk matrix visuals, goal-setting modules tailored to the Singaporean diet. Participants will also receive the DSHP Patient Information Leaflet (PIL) .
Study Locations (1 sites)
Jingfeng Sun, Singapore, Singapore 820681 Singapore
Eligibility Criteria
Inclusion Criteria for patients: * Participants who are 21 years old and above. * Participants who self-reports to have hypertension for at least six months and/ or taking at least one type of antihypertensive medication daily for at least six months * Able to read English Exclusion Criteria for patients: * Participants with type 1/ type 2 or secondary diabetes mellitus * Participants with CKD stage 3B and above * Participants with serum potassium of above 4.5mmol/L (on the latest blood test) * Participants with serum sodium of less than 135 mmol/L (on the latest blood test) * Participants who are on daily potassium chloride * Participants who are on diuretics (thiazide or thiazide like diuretics) * Participants who are pregnant * Participants who had been diagnosed with any terminal illnesses, visually impaired, disability or mental health related illnesses (visually impaired refers to individuals who self-report to have difficulty reading the wordings on the patient consent form, even with the use of visual aids) * Participants who are not clinically stable (Clinically stable patients are defined in this study as: * Has clinic BP 100-160/60-100 mmHg, Heart Rate (HR) 60-100 bpm * No recent hospitalizations (within the last 3 months) due to hypertensive emergencies, strokes, myocardial infarctions or other acute cardiovascular events * No recent symptoms such as severe dizziness, fainting, or chest pain) \*Participants who are on PRN potassium supplements is not an exclusion criteria Inclusion criteria for Healthcare providers: * HCPs who had prior experience in advising patients on dietary salt reduction * HCPs who self-reported to have ever treated patients with hypertension Exclusion criteria for healthcare providers -nil
Conditions Bipolar II Disorder, Bipolar II Disorder...
Phase NA
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Neurons are specialized types of cells that are responsible for carrying out the functions of the brain. Neurons communicate with electrical signals. In diseases such as major depression this electrical communication can go awry. One way to change brain function is using electrical stimulation to help alter the communication between groups of neurons in the brain. The purpose of this study is to test a personalized approach to brain stimulation as an intervention for bipolar depression The study researchers will use a surgically implanted device to measure each individual's brain activity related to his/her depression. The researchers will then use small electrical impulses to alter that brain activity and measure whether these changes help reduce depression symptoms. This study is intended for patients with major depression whose symptoms have not been adequately treated with currently available therapies. The device used in this study is called the NeuroPace Responsive Neurostimulation (RNS) System. It is currently FDA approved to treat patients with epilepsy. The study will test whether personalized responsive neurostimulation can safely and effectively treat bipolar depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: Device: Stimulation-ON — Active neurostimulation from the NeuroPace RNS® System triggered by a biomarker
  • Device: Device: Stimulation-OFF — No neurostimulation from the NeuroPace RNS® System
  • Device: Device: Stimulation -ON Active Control — Active neurostimulation from the NeuroPace RNS® System triggered with a fixed duty cycle

Primary Outcomes

  • Change in Montgomery-Asberg Depression Rating Scale (MADRS) score (Administered twice at baseline and every 2 weeks for the 36-40 weeks of Stage 3)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-16
Completion: 2035-06-28
Eligibility
Age: 22 Years and older
Sex: ALL
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Andrew Krystal
Principal Investigators:
  • Andrew Krystal, MD, MS (PRINCIPAL_INVESTIGATOR) - University of California, San Francisco
Contact Information
Study Contact:
Andrew Krystal, MD, MS
510-621-3193
trdepression@ucsf.edu
Natalie Becker, BS
510-621-3193
trdepression@ucsf.edu
Andrew Krystal, MD, MS
510-621-3193
trdepression@ucsf.edu
University of California, San Francisco
Interventions
  • Device: Device: Stimulation-ON — Active neurostimulation from the NeuroPace RNS® System triggered by a biomarker
  • Device: Device: Stimulation-OFF — No neurostimulation from the NeuroPace RNS® System
  • Device: Device: Stimulation -ON Active Control — Active neurostimulation from the NeuroPace RNS® System triggered with a fixed duty cycle
Study Locations (1 sites)
University of California, San Francisco, San Francisco, California 94143 United States
Eligibility Criteria
Inclusion Criteria: * Age 22-70 * Meet Diagnostic and Statistical Manual-V (DSM-V) diagnostic criteria for Bipolar II Disorder, with an episode of depression lasting at least 1 year that is treatment resistant as defined above, without a manic or hypomanic episode in the last 2 years; patients must be taking a mood stabilizer (lithium \>0.6 mEq/L or valproate \>350 mM/L), an atypical antipsychotic, or a combination of a mood stabilizer and an atypical antipsychotic for at least 2 weeks at a stable dosage before starting the study and must continue taking anti-manic medication throughout their participation in the study unless discontinuation is necessary because of patient safety/health considerations. * Must have either failed ECT (it was effective but not tolerated due to side effects; it was effective, but patients could not achieve a sustained response), not been able to complete a course of ECT due to side effects, or have been medically advised to receive ECT and have been unwilling or unable to obtain ECT. * Has MADRS score of \> 26 at two baseline visits * Ability to complete repeated administrations of MDD rating scales. * If patient is on a regimen of psychotropic medication, no changes in this regimen should be expected during the 4 weeks prior to entry into and the duration of the study. * Willing and able to undergo invasive brain recording/stimulation study * Willing and able to attend multiple research visits and perform at-home research protocol * Willing and able to provide informed consent * Ability to speak and read English Exclusion Criteria: * Meets DSM-V criteria for a psychotic disorder, eating disorder, panic disorder, posttraumatic stress disorder, obsessive compulsive disorder, tic disorder, or another comorbid psychiatric disorder other than MDD or generalized anxiety disorder based on a SCID * Generalized anxiety disorder is the primary DSM-V disorder during the current MDD episode * Active suicidal ideation with intent and plan as defined by a score of 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) * History of suicide attempt requiring hospitalization in previous 2 years. * Meets criteria for alcohol or substance abuse or dependence (other than caffeine) in previous 6 months, determined by the SCID * Has a personality disorder based on the investigator's assessment that the investigator believes will adversely impact subject compliance or safety * Fibromyalgia or chronic fatigue syndrome * Current condition requiring chronic narcotic use * History of traumatic brain injury, another neurological disorder, or developmental delay * History of seizures * MRI (done within one year of the first visit) with significant abnormalities * Previous ablative intracranial surgery or previously implanted deep brain stimulation system or any previously implanted device treatment involving brain stimulation * Implantable hardware not compatible with MRI or with the study * Major medical co-morbidities increasing the risk of surgery including severe diabetes, major organ system failure, history of hemorrhagic stroke, need for chronic anticoagulation other than aspirin, active infection, intracranial space occupying lesion, increased intracranial pressure, cardiovascular accident within the last month, aneurysm/abnormality, retinal detachment, unstable cardiovascular disease (recent myocardial infarction, severe ischemia, severe or uncontrolled hypertension), immunocompromised state, or malignancy with \< 5 years life expectancy * Inability to stop Coumadin or platelet anti-aggregation therapy for surgery and after surgery. - Patients taking these medications will need to discuss the need/risk of continuing these medications with their physicians and the PI or study personnel may contact the treating physician(s) to discuss the risks of anticoagulation/antiaggregation therapy discontinuation * Coagulopathy. Patients will be excluded unless assessed and cleared by hematology * Allergies or known hypersensitivity to materials in the NeuroPace RNS® System (i.e. titanium, polyurethane, silicone, polyetherimide, stainless steel) * Subject lives alone without possibility of caregiver support post-hospital stay * Inability to comply with study follow-up visits

JAK Signaling in Depression

NCT07003997
Recruiting
Conditions Major Depressive Disorder
Phase PHASE2
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will test the hypothesis that Janus kinase (JAK) signaling is involved in major depression (MD) with high inflammation by determining whether its inhibition with baricitinib can improve functional connectivity in reward and motor circuits in association with improved motivation and motor function in MD patients enriched for high C-reactive protein (CRP) and anhedonia.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Baricitinib — This small molecule, orally bioavailable agent is an immunosuppressant (a medicine that reduces the activity of the immune system). It works by blocking the action of enzymes known as Janus kinases (JAK). These enzymes play an important role in the processes of inflammation. Patients will receive a dose of 2 mg oral daily.
  • Drug: Placebo — A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 1 placebo tablet matching the baricitinib tablet.

Primary Outcomes

  • Change in corticostriatal FC in reward and motor circuits after 2 and 8 weeks of study medication (Baseline, week 2 and 8 post-intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-09-03
Completion: 2030-02
Eligibility
Age: 25 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Emory University
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Jennifer Felger, PhD (PRINCIPAL_INVESTIGATOR) - Emory University
Contact Information
Study Contact:
Jennifer Felger, PhD
404-727-3987
jfelger@emory.edu
Jennifer Felger, PhD
Emory University
Interventions
  • Drug: Baricitinib — This small molecule, orally bioavailable agent is an immunosuppressant (a medicine that reduces the activity of the immune system). It works by blocking the action of enzymes known as Janus kinases (JAK). These enzymes play an important role in the processes of inflammation. Patients will receive a dose of 2 mg oral daily.
  • Drug: Placebo — A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 1 placebo tablet matching the baricitinib tablet.
Study Locations (1 sites)
Emory University, Atlanta, Georgia 30322 United States
Eligibility Criteria
Inclusion Criteria: 1. willing and able to give written informed consent; 2. men or women, 25-55 years of age; 3. a primary diagnosis of DSM-V major depression, current, or Bipolar, depressed type as diagnosed by the SCID-V; 4. score of \>14 on the PHQ-9 from screening and HAM-D score ≥18 for study entry; 5. off all antidepressant or other psychotropic therapy (e.g. mood stabilizers, antipsychotics, and sedative hypnotics) for at least 4 weeks prior to baseline visit (8 weeks for fluoxetine), 6. CRP ≥3 mg/L, 7. PHQ-9 anhedonia score ≥2. Exclusion Criteria: 1. history or evidence (clinical and laboratory) of an autoimmune disorder 2. history or evidence (clinical or laboratory) of hepatitis B or C infection or human immunodeficiency virus infection; 3. history of any type of cancer requiring treatment with more than minor surgery; 4. unstable cardiovascular, endocrinologic, hematologic, hepatic, renal, or neurologic disease (as determined by physical examination, EKG and laboratory testing); 5. significant hematological abnormalities at screening (ANC \< 1500, Hgb\<10, platelet\< 100,000) 6. history of progressive multifocal leukoencephalopathy, 7. history of deep venous thrombosis, 8. history of cardiovascular disease (coronary artery disease, congestive heart failure, stroke - controlled hypertension is OK), 9. major surgery within 8 weeks prior to screening or will require major surgery during the study, 10. current or recent (\<4 weeks prior to randomization) viral (including COVID-19), bacterial, fungal, or parasitic infection or any other active or recent infection, 11. symptomatic herpes zoster infection at or within 12 weeks of randomization, 12. history of disseminated/complicated herpes zoster (for example, ophthalmic zoster or CNS involvement), 13. cirrhosis of the liver from any cause, 14. any of the following specific abnormalities on screening laboratory tests: ALT or AST \>2 x upper limits of normal (ULN), alkaline phosphatase (ALP) ≥2 x ULN, total bilirubin ≥1.5 x ULN (with the exception of patients on atazanavir, who must have total bilirubin \<2 x ULN), 15. chronic kidney disease with eGFR \<60 mL/min/1.73 m2, 16. history of any (non-mood-related) psychotic disorder; active psychotic symptoms of any type; substance abuse/dependence within 6 months of study entry (as determined by standardized clinician interview); 17. active suicidal plan as determined by a score \>3 on item #3 on the HAM-D; g. an active eating disorder (except for patients with binge eating disorder in whom binging is clearly associated with worsening of mood symptoms); 18. history of a cognitive disorder or traumatic head injury involving loss of consciousness; 19. pregnancy or lactation, 20. use of gender affirming hormone therapy; 21. chronic use of non-steroidal anti-inflammatory agents (NSAIDS) (excluding 81mg of aspirin), immunosuppressive (e.g., biologics), glucocorticoid containing medications or minocycline within 6 months, or non-prescription supplements with known or suspected anti-inflammatory properties (e.g. fish oil supplements) within 2 weeks of baseline, or at any time during the study; 22. any contraindication for MRI scanning; 23. failure of more than 2 antidepressant trials (at least 6 weeks at recommended dose) in the current episode or 5 antidepressant trials lifetime; and 24. BMI \>45 (to exclude severe obesity) or at the PI's discretion based on the patient's ability to fit comfortably in the MRI scanner.
Conditions Hypertension, Hypertension Complicated W...
Phase NA
Enrollment 100
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

iTHRIVE intervention is a 2-arm randomized controlled trial testing the effects of digital FARMacy, personalized dietitian coaching with produce prescriptions, and home blood pressure measurement in 100 hypertensive adults living in high food priority areas in counties in Maryland.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Behavioral: iTHRIVE intervention — Integration of three traditionally siloed components: 1. Digitally enabled food access 2. Personalized nutrition support 3. Clinical care-rision of home blood pressure device with app
  • Behavioral: Active comparator — Active comparator arm will receive enhanced usual care that consists of: 1. Standard produce bag 2. Home blood pressure Device without app 3. General dietary advice

Primary Outcomes

  • Systolic blood pressure (mmHg) (Baseline, 3, 6 and 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-25
Completion: 2028-03-20
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Johns Hopkins University
Collaborators: American Heart Association, National Institute on Minority Health and Health Disparities (NIMHD)
Principal Investigators:
  • Oluwabunmi Ogungbe, PhD, MPH, RN (PRINCIPAL_INVESTIGATOR) - Johns Hopkins School of Nursing
Contact Information
Study Contact:
Oluwabunmi Ogungbe, PhD, MPH, RN
410-614-1519
oogungb3@jh.edu
Yvonne Commodore-Mensah, PhD, MHS, RN
410614159
ycommod1@jhmi.edu
Margaret Utibe
410-873-7993
thrive-fim@jh.edu
Johns Hopkins Community Physicians
Interventions
  • Behavioral: iTHRIVE intervention — Integration of three traditionally siloed components: 1. Digitally enabled food access 2. Personalized nutrition support 3. Clinical care-rision of home blood pressure device with app
  • Behavioral: Active comparator — Active comparator arm will receive enhanced usual care that consists of: 1. Standard produce bag 2. Home blood pressure Device without app 3. General dietary advice
Study Locations (3 sites)
Johns Hopkins Community Physicians, Baltimore, Maryland 21205 United States
Johns Hopkins School of Nursing, Baltimore, Maryland 21205 United States
Holy Cross Hospital, Gaithersburg, Maryland 20876 United States
Eligibility Criteria
Inclusion Criteria: * 21-70 years * Self-identify as Black/African American or Hispanic/Latino * Have Stage 2 CKM defined as: * Systolic BP ≥130mmHg (measured at screening) AND at least one of: * Hypertension (ICD-10: I10-I16) * Prediabetes (HbA1c 5.7-6.4%) or Type 2 Diabetes (HbA1c ≥6.5%) * Stage 3 chronic kidney disease (CKD) (eGFR 30-59 mL/min/1.73m²) * Live in census tracts identified by the Montgomery/ Prince George's/Baltimore City County Departments of Planning as HFPA: * Healthy Food Availability Index score is low (0-9.5), * Median household income ≤185% of Federal Poverty Level * 30% of households have no vehicle, * Distance to supermarket \>1/4 mile. 5. Have refrigeration, food preparation appliances (microwave, stove), and cell phones for the App Exclusion Criteria: * Age \<21 years * Diagnosis of end-stage renal disease (ESRD), dialysis * Serious medical condition that either limits life expectancy or requires active management (e.g., cancer) * Significant food allergies, preferences, intolerances, or dietary requirements that would interfere with diet adherence * Active alcohol or substance use disorder (i.e., not sober/abstinent for ≥ 30 days) * Patients with cognitive impairment or other condition preventing their participation in the intervention * Pregnant, breastfeeding, or planning pregnancy * Current participation in a care management program related to health conditions (e.g., weight reduction, smoking cessation) or another clinical trial that could interfere with the study protocol * Planning to move out of the geographic area in 12 months
Conditions Pulmonary Hypertension, Heart Failure Wi...
Phase PHASE1, PHASE2
Enrollment 126
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Study of HS235 in Obese Participants with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Biological: HS235 — Subcutaneous Injection
  • Other: Placebo — Subcutaneous Injection

Primary Outcomes

  • Incidence and Number of Adverse Events (AEs) (Up to 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-08
Completion: 2030-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 126 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: 35Pharma Inc
Contact Information
Study Contact:
US GSK Clinical Trials Call Center
877-379-3718
GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center
+44 (0) 20 89904466
GSKClinicalSupportHD@gsk.com
Interventions
  • Biological: HS235 — Subcutaneous Injection
  • Other: Placebo — Subcutaneous Injection
Study Locations (1 sites)
Investigational Site-101, Greenville, South Carolina 29605 United States
Eligibility Criteria
Inclusion Criteria: Participants are eligible to be included in the study only if they meet at least all the following criteria: 1. Male or female, ≥ 18 years of age. 2. \[Sub-population A only - using a remote PAP sensor\]- Ambulatory PAP monitoring (e.g., CardioMEMS™ HF System or Cordella™ HF System) implanted in the course of standard of care at least 90 days before Screening. Hemodynamic evidence of PH with: 1. mPAP ≥ 25 mm Hg, as measured in supine position by the averaged 7-day values (weekly average) 2 weeks and 1 week before Randomization AND, 2. dPAP ≥ 15 mm Hg, as measured in supine position by the averaged 7-day values (weekly average) 2 weeks and 1 week before Randomization. 3. \[Sub-population B only - without a remote PAP sensor\] Hemodynamic evidence of PH based on the presence of all the following RHC parameters obtained during the Screening period, prior to randomization: 1. PVR ≥ 240 dyn\*sec/cm5 or ≥ 3 WU, and 2. mPAP \> 20 mmHg, and 3. PAWP \> 15 mmHg but \< 30 mmHg, and 4. dPAP ≥ 15 mmHg. 4. Established diagnosis of HFpEF with left ventricular ejection fraction (LVEF) ≥ 45 % as measured by echocardiography during Screening and and no documented LVEF \< 45% during the 2 years preceding Screening.. 5. New York Heart Association (NYHA) class II or III heart failure symptoms. 6. Stable diuretic regimen during the screening period. 7. Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) \< 90 at screening. 8. 6-minute walking distance (6MWD) ≥ 100 m at screening. 9. Body mass index ≥ 30 to ≤ 50 kg/m2 and Body weight ≤140 kg. 10. Ability to adhere to study visit schedule and understand and comply with all protocol requirements. Exclusion Criteria: 1. Hospitalization for any worsening medical condition or major surgery within 4 weeks prior to screening. 2. Occurrence of an acute coronary syndrome, percutaneous coronary intervention, or cardiac surgery within 90 days prior to Screening. 3. Implantation of a cardiac resynchronization therapy (CRT) device within 90 days before screening. 4. Planned cardiovascular revascularization or planned implantation of CRT device. 5. History of heart transplant or on heart transplant list. 6. History of serious or life-threatening cardiac arrhythmia within 90 days prior to screening. 7. Systemic hypotension or uncontrolled systemic hypertension. 8. History of Pericardial constriction or hypertrophic cardiomyopathy. 9. History of significant valvular stenosis or regurgitation. 10. Participants with a pneumonectomy or more than moderate Chronic Obstructive Pulmonary Disease (COPD) or mild interstitial lung disease (ILD) or mild obstructive sleep apnea (OSA).
Conditions Pulmonary Hypertension
Phase Not Applicable
Enrollment 150
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Patients with pulmonary arterial hypertension (PAH) are at increased risk of muscle loss and decreased physical activity. This study will aim to (1) understand the way in which muscle loss occurs in PAH, particularly the role of fat surrounding the heart, and (2) look at the impact muscle loss has on quality of life, daily physical activity, and hospitalizations in patients with PAH. The findings from this study could help identify potentially treatable factors that may improve the overall quality of life and physical functioning of patients with PAH. Subjects will be asked to attend a baseline visit where the following will be performed: * Measure your vital signs * Undergo a research blood draw, less than 4 tablespoons * Provide a urine pregnancy test (if applicable) * Review demographics, personal history, and medical history * Review current PAH medications * Complete questionnaires on how your PAH affects you * Complete a test of physical performance * Complete a grip strength test * Undergo an echocardiogram (Echo) * Complete a six-minute walk test * Undergo a Chest CT Scan * Undergo a scan of your body composition (DXA scan) * Obtain a weight and body composition measurement on the InBody Scale Subjects will also complete activity moniotring, two 24-hour diet recalls, and participate in remote follow-up visits every 6 months

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: blood draw — Research blood draw
  • Diagnostic Test: Short Performance Physical Battery — test of physical performance, which involves measuring movement from sitting to standing, walking speed, and balance
  • Diagnostic Test: Grip strength test — Measures grip strength
  • Diagnostic Test: Six minute walk test — Measures distance walked in 6 minutes
  • Radiation: Chest CT scan — X-ray and computer technology takes detailed pictures of the organs and structures inside your chest
  • Radiation: Dual-Energy X-ray Absorptiometry Scan — Uses X-ray technology to measure the mineral density of your bones, and provides a ratio of fat tissue to lean mass (muscle) and bone
  • Behavioral: Activity monitoring — A device worn on your non-dominant wrist which measures motion/ movement/ activity
  • Behavioral: 24 hour diet recall — A research dietitian will contact you and ask you to provide details of what you ate over the previous 24 hours

Primary Outcomes

  • Intake of food and nutrients (One time at Baseline)
  • Chest Computed Tomographic (CT) scan (One time at Baseline)
  • Epicardial adipose tissue (EAT) volume (One time at Baseline)
  • Metabolomics (One time at Baseline)
  • Right ventricular (RV) function (One time at Baseline)
  • Adiponectin (One time at Baseline)
  • Low lean mass (One time at Baseline)
  • Accelerometry measures (One time at Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-05-01
Completion: 2029-07-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Pennsylvania
Collaborators: National Heart, Lung, and Blood Institute (NHLBI), Rhode Island Hospital
Principal Investigators:
  • Nadine Al-Naamani, MD (PRINCIPAL_INVESTIGATOR) - University of Pennsylvania
Contact Information
Study Contact:
Rebecca Gallagher Research Project Manager, MSEd
215-294-9755
Rebecca.lang@Pennmedicine.upenn.edu
Nicole Denney, MS
215-615-4156
nicole.denney@pennmedicine.upenn.edu
Nicole Denney, MS
Nicole.denney@Pennmedicine.upenn.edu
University of Pennsylvania Hospital
Interventions
  • Diagnostic Test: blood draw — Research blood draw
  • Diagnostic Test: Short Performance Physical Battery — test of physical performance, which involves measuring movement from sitting to standing, walking speed, and balance
  • Diagnostic Test: Grip strength test — Measures grip strength
  • Diagnostic Test: Six minute walk test — Measures distance walked in 6 minutes
  • Radiation: Chest CT scan — X-ray and computer technology takes detailed pictures of the organs and structures inside your chest
Study Locations (2 sites)
University of Pennsylvania Hospital, Philadelphia, Pennsylvania 19104 United States
Rhode Island Hospital, Providence, Rhode Island 02903 United States
Eligibility Criteria
Inclusion Criteria: * Signed informed consent prior to initiation of any study mandated procedure. * Diagnosis of PAH belonging to one of the following subgroups of Group 1 PH according to the updated clinical classification \[Humbert 2022\] * Idiopathic (IPAH) * Heritable (HPAH) * Drugs or toxins induced * Associated (APAH) with one of the following: * Connective tissue disease; * Human immunodeficiency virus (HIV) infection; * Congenital heart disease; or * Portopulmonary hypertension * Diagnosis of PAH within 6 months of enrollment or diagnosis of PAH and on stable therapy for 3 months prior to enrollment * Documented hemodynamic diagnosis of PAH by right heart catheterization (RHC), prior to enrollment showing: * mPAP \> 20 mmHg; and * PAWP or LVEDP ≤ 15 mmHg * PVR \> 2 Wood units Exclusion Criteria: * Prior to enrollment, evidence of moderately severe obstructive ventilator defect with: * FEV1/FVC ≤ 5th percentile; and * FEV1 z-score \< -2.5 * Prior to enrollment, evidence of severe restrictive defect with * TLC \< 5th percentile * FEV1 z-score \< -4 * Prior to enrollment, hospitalization (within 1 week) for decompensated right heart failure * More than moderate aortic or mitral valve disease * LVEF \< 40% within 1 year of screening * Pregnancy